Condition

Lipidemia

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions11

Lead sponsors shown3

Clinical trials

3 shown

A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic SyndromeNCT07219602 · 2025-12-11

ACTIVE_NOT_RECRUITING

Oleocanthal Rich Olive Oil Acute Effects on Hyperglycemia and Platelet Activation in T2DMNCT04419948 · 2019-05-16

UNKNOWN

Common interventions

ButterOTHER1 EVOO with 250 mg/kg oleocanthalOTHER1 EVOO with 500 mg/kg oleocanthalOTHER1 gastric bypassPROCEDURE1 IbuprofenOTHER1 Obicetrapib 10 mgDRUG1 obicetrapib 10 mg + ezetimibe 10 mg FDC dailyDRUG1 PlaceboOTHER1 Refined olive oilOTHER1 sleeve gastrectomyPROCEDURE1 White breadOTHER1

Leading sponsors

First Affiliated Hospital of Jinan University1 Harokopio University1 NewAmsterdam Pharma1

Trial status mix

UNKNOWN2

ACTIVE_NOT_RECRUITING1

Phase mix

NA2

PHASE31

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.